Only qualified healthcare providers may order

Global Screening Array + Interpretation

This test analyzes a DNA sample for changes in genes associated with actionable results for a patient. Most of the 59 genes are associated with Carrier Status of either a hereditary form of cardiovascular disease or cancer risk. Cancer risks include breast, ovarian, colon, thyroid, and other types of cancer. Other genes included in the screening are associated with Pharmacogenetics—certain reactions or non-reactions to medications and Adult-onset Actionable Variant Status for those carriers of a known hereditary rare disease.

This test(s) was developed, and performance characteristics were determined by the HudsonAlpha Clinical Services Lab, LLC. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. These tests are used for clinical purposes, and therefore validation was done as required under the requirements of the Clinical Laboratory Improvement Act (CLIA) of 1988. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The chance of a false negative or a false-positive result due to laboratory error cannot be completely excluded. These results should not be regarded as investigational or for research.